NEUROPACE INC
NPCENASDAQTrading Snapshot
- Day Range
- $13.74 – $14.13
- 52-Week Range
- $9.22 – $19.60
- Volume
- $3.35B
- Avg Volume
- $3.26B
- Shares Outstanding
- 34.1M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $100M
- Last Q Revenue
- $23M
- P/E Ratio
- -24.4
- P/S Ratio
- 4.8x
- EPS (TTM)
- $-0.56
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.4%
Why Investors Own NPCE
- ✓High-growth profile — revenue up +8.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEUROPACE INC
NPCE
StockOtter · stockotter.spaceAbout NEUROPACE INC
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE
Bank of America Corp DE reduced its stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) by 85.5% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 24,698 shares of the compa
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc.
BlackRock Inc. bought a new stake in NeuroPace, Inc. (NASDAQ: NPCE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,477,6
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate